Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells

Oncology Reports

Volumn 28, Issue 1, 2012, Pages 105-110

  Uehara, Norihisa ^a   Yoshizawa, Katsuhiko ^a   Tsubura, Airo ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Breast cancer; p21; p27; SCF Skp2 Cks1 ubiquitin ligase; Vorinostat

Indexed keywords

BROXURIDINE; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE SUBUNIT 1; CYCLIN E; CYCLOHEXIMIDE; MESSENGER RNA; PROTEIN P21; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; PHARMACOLOGICAL BLOCKING; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STABILITY; S PHASE CELL CYCLE CHECKPOINT; TRANSCRIPTION INITIATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CDC2-CDC28 KINASES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA REPLICATION; FEMALE; HUMANS; HYDROXAMIC ACIDS; PROTEIN STABILITY; PROTEOLYSIS; S-PHASE KINASE-ASSOCIATED PROTEINS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 84861555689     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1758     Document Type: Article

References (28)

1. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999. (Pubitemid 29297917)
2. Reed SI: Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover. Nat Rev Mol Cell Biol 4: 855-864, 2003.
3. Catzavelos C, Bhattacharya N, Ung YC, et al: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3: 227-230, 1997. (Pubitemid 27064710)
4. Slingerland J and Pagano M: Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 183: 10-17, 2000. (Pubitemid 30130220)
5. Hershko DD: Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer 112: 1415-1424, 2008.
6. Signoretti S, Di Marcotullio L, Richardson A, et al: Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 110: 633-641, 2002. (Pubitemid 34988787)
7. Slotky M, Shapira M, Ben-Izhak O, et al: The expression of the ubiquitin ligase subunit Cks1 in human breast cancer. Breast Cancer Res 7: R737-R744, 2005.
8. Sonoda H, Inoue H, Ogawa K, Utsunomiya T, Masuda TA and Mori M: Significance of skp2 expression in primary breast cancer. Clin Cancer Res 12: 1215-1220, 2006. (Pubitemid 43342511)
9. Traub F, Mengel M, Luck HJ, Kreipe HH and von Wasielewski R: Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat 99: 185-191, 2006. (Pubitemid 44268266)
10. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006. (Pubitemid 44348499)
11. Richon VM, Garcia-Vargas J and Hardwick JS: Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 280: 201-210, 2009.
12. Huang L, Sowa Y, Sakai T and Pardee AB: Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19: 5712-5719, 2000.
13. Bali P, Pranpat M, Swaby R, et al: Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplifi- cation of her-2. Clin Cancer Res 11: 6382-6389, 2005. (Pubitemid 41262970)
14. Huang L and Pardee AB: Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6: 849-866, 2000.
15. Uehara N, Kanematsu S, Miki H, Yoshizawa K and Tsubura A: Requirement of p38 MAPK for a cell-death pathway triggered by vorinostat in MDA-MB-231 human breast cancer cells. Cancer Lett 315: 112-121, 2012.
16. Uehara N, Unami A, Kiyozuka Y, Shikata N, Oishi Y and Tsubura A: Parous mammary glands exhibit distinct alterations in gene expression and proliferation responsiveness to carcinogenic stimuli in Lewis rats. Oncol Rep 15: 903-911, 2006.
17. Uehara N, Matsuoka Y and Tsubura A: Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol Cancer Res 6: 186-193, 2008. (Pubitemid 351342406)
18. Kanematsu S, Uehara N, Miki H, et al: Autophagy inhibition enhances sulforaphane-induced apoptosis in human breast cancer cells. Anticancer Res 30: 3381-3390, 2010.
19. Nakayama KI and Nakayama K: Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol 16: 323-333, 2005.
20. Chen JS and Faller DV: Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts. J Cell Physiol 202: 87-99, 2005. (Pubitemid 39603365)
21. Schneider G, Reichert M, Saur D, Hamacher R, Fritsch R and Schmid RM: HDAC3 is linked to cell cycle machinery in MiaPaCa2 cells by regulating transcription of skp2. Cell Prolif 40: 522-531, 2007. (Pubitemid 47063293)
22. Bornstein G, Bloom J, Sitry-Shevah D, Nakayama K, Pagano M and Hershko A: Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem 278: 25752-25757, 2003. (Pubitemid 36835332)
23. Carrano AC, Eytan E, Hershko A and Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1: 193-199, 1999. (Pubitemid 129500937)
24. Tsvetkov LM, Yeh KH, Lee SJ, Sun H and Zhang H: p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 9: 661-664, 1999.
25. Alao JP, Lam EW, Ali S, et al: Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res 10: 8094-8104, 2004. (Pubitemid 39587551)
26. Ganoth D, Bornstein G, Ko TK, Larsen B, Tyers M, Pagano M and Hershko A: The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol 3: 321-324, 2001. (Pubitemid 32201330)
27. Spruck C, Strohmaier H, Watson M, et al: A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Mol Cell 7: 639-650, 2001. (Pubitemid 32706355)
28. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA and Richon VM: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61: 8492-8497, 2001. (Pubitemid 33131130)